$OPK
OPKO HEALTH, INC. Stock $opk

$opk Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000143774923021962 Filed on August 03, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q4
Revenue	$178.6M	$265.4M	$185.3M
YoY Change	-0.64%	-14.36%	-53.82%
Cost Of Revenue	$130.9M	$138.9M	$129.3M
YoY Change	-11.82%	-28.52%	-55.83%
Gross Profit	$47.70M	$126.5M	$55.99M
YoY Change	52.4%	9.45%	-48.4%
Gross Profit Margin	26.71%	47.66%	30.21%
Selling, General & Admin	$72.24M	$79.80M	$74.00M
YoY Change	-9.33%	-21.35%	-46.46%
% of Gross Profit	151.45%	63.08%	132.15%
Research & Development	$19.44M	$18.20M	$19.53M
YoY Change	3.42%	5.48%	-7.04%
% of Gross Profit	40.74%	14.39%	34.88%
Depreciation & Amortization	$26.18M	$21.50M	$26.46M
YoY Change	-6.47%	-23.2%	37.88%
% of Gross Profit	54.89%	17.0%	47.26%
Operating Expenses	$243.0M	$119.5M	$240.6M
YoY Change	-9.18%	-62.73%	-48.19%
Operating Profit	-$64.41M	$7.000M	-$184.6M
YoY Change	-26.66%	-165.18%	-48.13%
Interest Expense	$3.384M	$3.277M	-$2.162M
YoY Change	-277.73%	-227.21%	-46.3%
% of Operating Profit		46.81%
Other Income/Expense, Net	-$13.97M	-$23.50M	-$44.75M
YoY Change	-63.76%	-68.9%	-3550.35%
Pretax Income	-$78.38M	-$16.50M	-$102.2M
YoY Change	-37.98%	-80.88%	55.26%
Income Tax	$6.075M	$3.100M	-$16.98M
% Of Pretax Income
Net Earnings	-$84.47M	-$19.60M	-$85.23M
YoY Change	-1.88%	-80.72%	15.53%
Net Earnings / Revenue	-47.3%	-7.39%	-45.99%
Basic Earnings Per Share	-$0.11	-$0.03	-$0.11
Diluted Earnings Per Share	-$0.11	-$0.03	-$0.11
COMMON SHARES
Basic Shares Outstanding	773.1M	772.7M shares	772.7M shares
Diluted Shares Outstanding	751.5M

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$138.6M	$108.1M	$153.2M
YoY Change	-23.36%	-48.64%	13.72%
Cash & Equivalents	$138.6M	$108.1M	$153.2M
Short-Term Investments
Other Short-Term Assets	$7.003M	$325.7M	$6.252M
YoY Change	10.46%	5022.68%	0.92%
Inventory	$68.96M	$73.75M	$74.06M
Prepaid Expenses
Receivables	$117.4M	$211.0M	$127.3M
Other Receivables	$9.100M	$17.11M	$21.30M
Total Short-Term Assets	$357.2M	$433.8M	$394.5M
YoY Change	-13.7%	-12.32%	-52.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$78.17M	$78.88M	$121.6M
YoY Change	-34.72%	-34.82%	-1.9%
Goodwill	$594.5M	$597.4M	$595.9M
YoY Change	3.65%	3.2%	14.45%
Intangibles	$758.4M	$782.2M	$823.5M
YoY Change
Long-Term Investments	$19.40M	$27.78M	$28.08M
YoY Change	-75.07%	-74.44%	161.72%
Other Assets	$9.333M	$932.7M	$8.679M
YoY Change	-3.14%	10382.13%	-8.97%
Total Long-Term Assets	$1.699B	$1.725B	$1.773B
YoY Change	-6.15%	-7.99%	12.43%
TOTAL ASSETS
Total Short-Term Assets	$357.2M	$433.8M	$394.5M
Total Long-Term Assets	$1.699B	$1.725B	$1.773B
Total Assets	$2.057B	$2.159B	$2.167B
YoY Change	-7.56%	-8.89%	-9.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$66.80M	$87.90M	$66.99M
YoY Change	34.28%	56.66%	-18.34%
Accrued Expenses	$92.37M	$98.60M	$98.27M
YoY Change	-17.54%	-23.12%	-49.21%
Deferred Revenue			$0.00
YoY Change			-100.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.772M	$0.00	$39.40M
YoY Change	-98.16%	-100.0%	132.42%
Total Short-Term Liabilities	$200.6M	$226.4M	$213.5M
YoY Change	-24.96%	5.07%	-35.31%
LONG-TERM LIABILITIES
Long-Term Debt	$7.927M	$212.3M	$226.6M
YoY Change	-94.89%	-2.5%	17.34%
Other Long-Term Liabilities	$25.62M	$51.90M	$27.37M
YoY Change	13.59%	219.64%	81.72%
Total Long-Term Liabilities	$411.6M	$264.2M	$392.1M
YoY Change	25.3%	-39.31%	1.96%
TOTAL LIABILITIES
Total Short-Term Liabilities	$200.6M	$226.4M	$213.5M
Total Long-Term Liabilities	$411.6M	$264.2M	$392.1M
Total Liabilities	$612.1M	$623.6M	$605.6M
YoY Change	2.75%	-4.18%	-15.25%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.945B	-$1.861B	-$1.823B
YoY Change	11.95%	12.67%	20.57%
Common Stock	$7.817M	$7.817M	$7.813M
YoY Change	0.04%	0.14%	13.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.445B	$1.535B	$1.562B
YoY Change
Total Liabilities & Shareholders Equity	$2.057B	$2.159B	$2.167B
YoY Change	-7.56%	-8.89%	-9.69%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q4
OPERATING ACTIVITIES
Net Income	-$84.47M	-$19.60M	-$85.23M
YoY Change	-1.88%	-80.72%	15.53%
Depreciation, Depletion And Amortization	$26.18M	$21.50M	$26.46M
YoY Change	-6.47%	-23.2%	37.88%
Cash From Operating Activities	$33.10M	-$365.0K	-$31.62M
YoY Change	-202.68%	-96.82%	460.34%
INVESTING ACTIVITIES
Capital Expenditures	$4.200M	$6.013M	$6.336M
YoY Change	-155.18%	-211.79%	-194.15%
Acquisitions
YoY Change
Other Investing Activities	$700.0K	$522.0K	-$1.536M
YoY Change	-76.11%	-99.54%	-21.19%
Cash From Investing Activities	-$3.600M	-$5.491M	-$7.872M
YoY Change	-23.11%	-105.06%	-9.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.100M	3.462M	10.14M
YoY Change	-75.13%	-71.79%	1119.23%
NET CHANGE
Cash From Operating Activities	33.10M	-365.0K	-31.62M
Cash From Investing Activities	-3.600M	-5.491M	-7.872M
Cash From Financing Activities	2.100M	3.462M	10.14M
Net Change In Cash	31.60M	-2.394M	-29.35M
YoY Change	-210.98%	-102.19%	117.55%
FREE CASH FLOW
Cash From Operating Activities	$33.10M	-$365.0K	-$31.62M
Capital Expenditures	$4.200M	$6.013M	$6.336M
Free Cash Flow	$28.90M	-$6.378M	-$37.96M
YoY Change	-217.37%	4.59%	-3591.81%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	781693135
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	781306164
CY2023Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	8655082
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	8655082
CY2022Q4	opk	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Goodwill And Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets	1600000000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1000000000.0	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	pure
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-33528
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	75-2402409
	dei	Entity Address Address Line1 EntityAddressAddressLine1	4400 Biscayne Blvd.
	dei	Entity Address City Or Town EntityAddressCityOrTown	Miami
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33137
	dei	City Area Code CityAreaCode	305
	dei	Local Phone Number LocalPhoneNumber	575-4100
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
	dei	Trading Symbol TradingSymbol	OPK
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	773056533
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	108108000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	153191000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	210982000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	127312000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	73749000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	74060000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	40950000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	39962000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	433789000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	394525000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	78876000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	82879000	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	782195000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	823520000	usd
CY2023Q2	opk	Capitalized Research And Development In Process CapitalizedResearchAndDevelopmentInProcess	195000000	usd
CY2022Q4	opk	Capitalized Research And Development In Process CapitalizedResearchAndDevelopmentInProcess	195000000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	597375000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	595851000	usd
CY2023Q2	us-gaap	Long Term Investments LongTermInvestments	27783000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	28080000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	34938000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	38725000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8943000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8679000	usd
CY2023Q2	us-gaap	Assets Assets	2158899000	usd
CY2022Q4	us-gaap	Assets Assets	2167259000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	87877000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	66993000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	98604000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	98269000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11240000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11628000	usd
CY2023Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3050000	usd
CY2023Q2	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	28729000	usd
CY2022Q4	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	33540000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	226450000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	213480000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	24912000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27963000	usd
CY2023Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	212299000	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	210371000	usd
CY2023Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	133049000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	126426000	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	26841000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	27371000	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	397101000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	392131000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	623551000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	605611000	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	7817000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	7813000	usd
CY2023Q2	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	1791000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	1791000	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3427094000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3421872000	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-36942000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-43323000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1860830000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1822923000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	1535348000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1561648000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2158899000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2167259000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	265418000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	309893000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	502995000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	639111000	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	79794000	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	101464000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	155436000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	219000000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18159000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17254000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50764000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35566000	usd
CY2023Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-34000	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	175000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	102000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	69000	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21535000	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22793000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	43009000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	44818000	usd
CY2023Q2	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-0	usd
CY2022Q2	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	15365000	usd
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-0	usd
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	15365000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	258393000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	320632000	usd
	us-gaap	Operating Expenses OperatingExpenses	526564000	usd
	us-gaap	Operating Expenses OperatingExpenses	722275000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	7025000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-10739000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-23569000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-83164000	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	1077000	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	161000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2107000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	171000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	3277000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	3075000	usd
	us-gaap	Interest Expense InterestExpense	6668000	usd
	us-gaap	Interest Expense InterestExpense	5737000	usd
CY2023Q2	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	142000	usd
CY2022Q2	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	338000	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-917000	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	206000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-21417000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-72997000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4400000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-74439000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-23475000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-75573000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9878000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-79799000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-16450000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-86312000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-33447000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-162963000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3148000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15070000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4381000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6196000	usd
CY2023Q2	opk	Income Loss From Continuing Operations Net Of Tax Before Equity Method Investments And Noncontrolling Interest Total IncomeLossFromContinuingOperationsNetOfTaxBeforeEquityMethodInvestmentsAndNoncontrollingInterestTotal	-19598000	usd
CY2022Q2	opk	Income Loss From Continuing Operations Net Of Tax Before Equity Method Investments And Noncontrolling Interest Total IncomeLossFromContinuingOperationsNetOfTaxBeforeEquityMethodInvestmentsAndNoncontrollingInterestTotal	-101382000	usd
	opk	Income Loss From Continuing Operations Net Of Tax Before Equity Method Investments And Noncontrolling Interest Total IncomeLossFromContinuingOperationsNetOfTaxBeforeEquityMethodInvestmentsAndNoncontrollingInterestTotal	-37828000	usd
	opk	Income Loss From Continuing Operations Net Of Tax Before Equity Method Investments And Noncontrolling Interest Total IncomeLossFromContinuingOperationsNetOfTaxBeforeEquityMethodInvestmentsAndNoncontrollingInterestTotal	-156767000	usd
CY2023Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-42000	usd
CY2022Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-268000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-79000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-316000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-19640000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-101650000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-37907000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-157083000	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	751727383
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	712548661
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	751617431
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	686597899
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-19640000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-101650000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-37907000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-157083000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	670000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-17756000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	6381000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-18676000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18970000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-119406000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31526000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-175759000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1551810000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2810000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	-301000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-19640000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	669000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	1535348000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1561648000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5527000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	-301000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-37907000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	6381000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	1535348000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	1614883000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4308000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	-360000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	219374000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-101650000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-17756000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	1718799000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1685126000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11925000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	-225000	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	219374000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-157083000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-18676000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	1718799000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-37907000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-157083000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	52993000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	55809000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	1364000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	1364000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	598000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	569000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-79000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-316000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5527000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	11925000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-2075000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	477000	usd
	opk	Changes In Fair Value Gain Loss In Equity Securities Fvni And Derivative Instruments ChangesInFairValueGainLossInEquitySecuritiesFvniAndDerivativeInstruments	-6146000	usd
	opk	Changes In Fair Value Gain Loss In Equity Securities Fvni And Derivative Instruments ChangesInFairValueGainLossInEquitySecuritiesFvniAndDerivativeInstruments	-73724000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	102000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	69000	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-0	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	15365000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1753000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-8942000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	81822000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-95864000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2749000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2864000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1279000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6502000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1915000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	260000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	20210000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-19508000	usd
	opk	Increase Decrease In Foreign Currency Measurement IncreaseDecreaseInForeignCurrencyMeasurement	-1318000	usd
	opk	Increase Decrease In Foreign Currency Measurement IncreaseDecreaseInForeignCurrencyMeasurement	4295000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-17000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5073000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-69978000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23012000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-31333000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	5000000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	-0	usd
	us-gaap	Proceeds From Divestiture Of Interest In Subsidiaries And Affiliates ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates	0	usd
	us-gaap	Proceeds From Divestiture Of Interest In Subsidiaries And Affiliates ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates	115423000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-0	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	2071000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	842000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	870000	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	9050000	usd
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	10630000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13208000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	103592000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1000	usd
	opk	Proceeds From Stock Options Exercised Net ProceedsFromStockOptionsExercisedNet	301000	usd
	opk	Proceeds From Stock Options Exercised Net ProceedsFromStockOptionsExercisedNet	225000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	341850000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	684467000	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	348206000	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	679860000	usd
	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	3000000	usd
	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	-0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-9657000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4383000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	794000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-894000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-45083000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	75748000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	153191000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	134710000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108108000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	210458000	usd
	us-gaap	Interest Paid Net InterestPaidNet	4204000	usd
	us-gaap	Interest Paid Net InterestPaidNet	3554000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	685000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4647000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	181000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
	opk	Common Stock Options And Warrants Net Exercised CommonStockOptionsAndWarrantsNetExercised	301000	usd
	opk	Common Stock Options And Warrants Net Exercised CommonStockOptionsAndWarrantsNetExercised	655000	usd
	opk	Stock Issued As Part Of An Acquisition Cash Flow Impact StockIssuedAsPartOfAnAcquisitionCashFlowImpact	0	usd
	opk	Stock Issued As Part Of An Acquisition Cash Flow Impact StockIssuedAsPartOfAnAcquisitionCashFlowImpact	219374000	usd
	opk	Shares Included In Business Divesture Cash Flow Impact SharesIncludedInBusinessDivestureCashFlowImpact	6689000	usd
	opk	Shares Included In Business Divesture Cash Flow Impact SharesIncludedInBusinessDivestureCashFlowImpact	172000000	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	33500000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	39900000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"><i>Use of estimates</i>. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from these estimates.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p>
CY2023Q2	us-gaap	Inventory Write Down InventoryWriteDown	800000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	2200000	usd
CY2022Q2	us-gaap	Inventory Write Down InventoryWriteDown	300000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	1000000.0	usd
CY2023Q2	opk	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Goodwill And Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets	1600000000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	597400000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	595900000	usd
CY2023Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1000000000.0	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21500000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	43000000.0	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22800000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	44800000	usd
CY2023Q2	us-gaap	Depreciation Depreciation	5000000.0	usd
	us-gaap	Depreciation Depreciation	10000000.0	usd
CY2022Q2	us-gaap	Depreciation Depreciation	5200000	usd
	us-gaap	Depreciation Depreciation	11000000.0	usd
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	6000000.0	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"><i>Concentration of credit risk and allowance for credit losses</i>. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable. Substantially all of our accounts receivable are with either companies in the healthcare industry or patients. However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">While we have receivables due from federal and state governmental agencies, such receivables are <em style="font: inherit;">not</em> a credit risk because federal and state governments fund the related healthcare programs. Payment is primarily dependent upon submitting appropriate documentation. On <em style="font: inherit;"> June 30, 2023</em> and <em style="font: inherit;"> December 31, 2022</em>, receivable balances (net of explicit and implicit price concessions) from Medicare and Medicaid were 7% and 14%, respectively, of our consolidated Accounts receivable, net.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The portion of our accounts receivable due from individual patients comprises the largest portion of credit risk. At <em style="font: inherit;"> June 30, 2023</em> and <em style="font: inherit;"> December 31, 2022</em>, receivables due from patients represented approximately 1.8% and 2.9%, respectively, of our consolidated Accounts receivable, net.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">We assess the collectability of accounts receivable balances by considering factors such as historical collection experience, customer credit worthiness, the age of accounts receivable balances, regulatory changes and current economic conditions and trends that <em style="font: inherit;"> may </em>affect a customer’s ability to pay. Actual results could differ from those estimates. The allowance for credit losses was $2.0 million and $4.2 million on <em style="font: inherit;"> June 30, 2023</em>, and <em style="font: inherit;"> December 31, 2022</em>, respectively. The credit loss expense for the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2023</em>, was $2.8 thousand and $88.0 thousand, respectively. The credit loss expense for the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022</em>, was $96.0 thousand and $183.6 thousand, respectively.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p>
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2000000.0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4200000	usd
CY2023Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2800	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	88000.0	usd
CY2022Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	96000.0	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	183600	usd
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	2800000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5500000	usd
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	4300000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	11900000	usd
CY2023Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	900000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2000000.0	usd
CY2022Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	800000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1800000	usd
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	7990000	usd
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	82817175
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	56605791
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	82438648
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	57016847
CY2023Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2023Q2	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	549680
CY2023Q2	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	386971
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	549680
	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	386971
CY2022Q2	opk	Options And Warrants Exercised During Period OptionsAndWarrantsExercisedDuringPeriod	789063
CY2022Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	546337
CY2022Q2	opk	Options And Warrants Exercised During Period OptionsAndWarrantsExercisedDuringPeriod	789063
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	242726
	opk	Options And Warrants Exercised During Period OptionsAndWarrantsExercisedDuringPeriod	844813
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	602087
	opk	Options And Warrants Exercised During Period OptionsAndWarrantsExercisedDuringPeriod	844813
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	242726
CY2023Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	213021000	usd
CY2022Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	131474000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2039000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4162000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	210982000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	127312000	usd
CY2023Q2	us-gaap	Other Inventory Supplies OtherInventorySupplies	29326000	usd
CY2022Q4	us-gaap	Other Inventory Supplies OtherInventorySupplies	31275000	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	36460000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	37139000	usd
CY2023Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	3667000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2449000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	6771000	usd
CY2023Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3694000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3574000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	73749000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	74060000	usd
CY2023Q2	us-gaap	Prepaid Taxes PrepaidTaxes	8138000	usd
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	8191000	usd
CY2023Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	10414000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	7918000	usd
CY2023Q2	us-gaap	Prepaid Insurance PrepaidInsurance	6214000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	4496000	usd
CY2023Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	8973000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	13105000	usd
CY2023Q2	us-gaap	Other Assets Current OtherAssetsCurrent	7211000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	6252000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	40950000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	39962000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	444373000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	398959000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	782195000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	823520000	usd
CY2023Q2	opk	Accrued Inventory Not Yet Billed AccruedInventoryNotYetBilled	1964000	usd
CY2022Q4	opk	Accrued Inventory Not Yet Billed AccruedInventoryNotYetBilled	7830000	usd
CY2023Q2	opk	Accrued Commitments And Contingencies Current AccruedCommitmentsAndContingenciesCurrent	3252000	usd
CY2022Q4	opk	Accrued Commitments And Contingencies Current AccruedCommitmentsAndContingenciesCurrent	4295000	usd
CY2023Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	36734000	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	33765000	usd
CY2023Q2	opk	Accrued Clinical Trials AccruedClinicalTrials	11700000	usd
CY2022Q4	opk	Accrued Clinical Trials AccruedClinicalTrials	4700000	usd
CY2023Q2	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	67000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	62000	usd
CY2023Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2809000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2809000	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1943000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1820000	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	40135000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	42988000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	98604000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	98269000	usd
CY2023Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1072000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	974000	usd
CY2023Q2	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	8411000	usd
CY2022Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	9098000	usd
CY2023Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	7270000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	7089000	usd
CY2023Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	140000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	138000	usd
CY2023Q2	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	9948000	usd
CY2022Q4	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	10072000	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	26841000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	27371000	usd
CY2022Q4	us-gaap	Goodwill Gross GoodwillGross	633874000	usd
CY2023Q2	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	38023000	usd
	opk	Goodwill Acquired Disposed Of During Period GoodwillAcquiredDisposedOfDuringPeriod	-172000	usd
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	1696000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	597375000	usd
CY2023Q2	opk	Equity Method Investment Excluding Variable Interest Entity EquityMethodInvestmentExcludingVariableInterestEntity	30000	usd
CY2023Q2	us-gaap	Equity Method Investment Underlying Equity In Net Assets EquityMethodInvestmentUnderlyingEquityInNetAssets	2622000	usd
CY2022Q4	opk	Equity Method Investment Excluding Variable Interest Entity EquityMethodInvestmentExcludingVariableInterestEntity	103000	usd
CY2022Q4	us-gaap	Equity Method Investment Underlying Equity In Net Assets EquityMethodInvestmentUnderlyingEquityInNetAssets	4120000	usd
CY2023Q2	opk	Equity Method Investment Variable Interest Entity EquityMethodInvestmentVariableInterestEntity	795000	usd
CY2023Q2	opk	Equity Method Investment Variable Interest Entity Underlying Equity In Net Assets EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets	970000	usd
CY2022Q4	opk	Equity Method Investment Variable Interest Entity EquityMethodInvestmentVariableInterestEntity	800000	usd
CY2022Q4	opk	Equity Method Investment Variable Interest Entity Underlying Equity In Net Assets EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets	1370000	usd
CY2023Q2	us-gaap	Equity Method Investments Fair Value Disclosure EquityMethodInvestmentsFairValueDisclosure	21209000	usd
CY2022Q4	us-gaap	Equity Method Investments Fair Value Disclosure EquityMethodInvestmentsFairValueDisclosure	21120000	usd
CY2023Q2	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	330000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	648000	usd
CY2023Q2	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	5381000	usd
CY2022Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	5381000	usd
CY2023Q2	opk	Equity Investments Carrying Value Of Equity Intruments EquityInvestmentsCarryingValueOfEquityIntruments	38000	usd
CY2022Q4	opk	Equity Investments Carrying Value Of Equity Intruments EquityInvestmentsCarryingValueOfEquityIntruments	28000	usd
CY2023Q2	us-gaap	Long Term Investments LongTermInvestments	27783000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	28080000	usd
CY2023Q2	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	1700000	usd
CY2022Q4	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	1300000	usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-318000	usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-2718000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-318000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-2718000	usd
CY2023Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	2657000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1720000	usd
CY2023Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	8501000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9290000	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	249529000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	256251000	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	249529000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	256251000	usd
CY2023Q2	us-gaap	Line Of Credit Facility Interest Rate At Period End LineOfCreditFacilityInterestRateAtPeriodEnd		pure
CY2023Q2	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	80028000	usd
CY2023Q2	us-gaap	Line Of Credit LineOfCredit	26072000	usd
CY2022Q4	us-gaap	Line Of Credit LineOfCredit	31820000	usd
CY2019Q3	opk	Operating Leases Monthly Payments Year Five OperatingLeasesMonthlyPaymentsYearFive	101000	usd
CY2023Q2	us-gaap	Purchase Obligation PurchaseObligation	46400000	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1036000	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	102000	usd
	opk	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Foreign Currency Impact FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignCurrencyImpact	1000	usd
CY2023Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1139000	usd
CY2023Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	1100000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	1000000.0	usd
CY2019Q3	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	29500
CY2019Q3	opk	Operating Leases Monthly Payments Year One OperatingLeasesMonthlyPaymentsYearOne	89000	usd
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	13900000	usd
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	21200000	usd
CY2023Q2	opk	Accrued Expense Payor Overpayment Reimbursement Liability AccruedExpensePayorOverpaymentReimbursementLiability	2900000	usd
CY2022Q4	opk	Accrued Expense Payor Overpayment Reimbursement Liability AccruedExpensePayorOverpaymentReimbursementLiability	1800000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	138000	usd
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	140000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-2000	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	pure
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	7025000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-10739000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-23569000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-83164000	usd
CY2023Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	26391000	usd
CY2022Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	27995000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	52993000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	55809000	usd
CY2023Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-42000	usd
CY2022Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-268000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-79000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-316000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	265418000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	309893000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	502995000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	639111000	usd
CY2023Q2	us-gaap	Assets Assets	2158899000	usd
CY2022Q4	us-gaap	Assets Assets	2167259000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	597375000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	595851000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	34938000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	38725000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11240000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11628000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	24912000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27963000	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y
CY2023Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P6Y9M18D
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P6Y6M
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.046	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.044	pure
CY2023Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.046	pure
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.038	pure
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	6442000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	1804000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	8844000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	2737000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5567000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	2061000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4114000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	1394000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3858000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	588000	usd
CY2023Q2	opk	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	11910000	usd
CY2023Q2	opk	Finance Lease Liability Payments Due After Year Four FinanceLeaseLiabilityPaymentsDueAfterYearFour	1959000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	40735000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	10543000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4583000	usd
CY2023Q2	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	464000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	36152000	usd
CY2023Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	10079000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	8300000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1400000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	600000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	8400000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1900000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	1300000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	7955000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	8327000	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	206000	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	52000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1268000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	724000	usd
	opk	Payments For Leases PaymentsForLeases	9429000	usd
	opk	Payments For Leases PaymentsForLeases	9103000	usd

Files In Submission

Name	View Source	Status
0001437749-23-021962-index-headers.html	Edgar Link	pending
0001437749-23-021962-index.html	Edgar Link	pending
0001437749-23-021962.txt	Edgar Link	pending
0001437749-23-021962-xbrl.zip	Edgar Link	pending
ex_519394.htm	Edgar Link	pending
ex_519395.htm	Edgar Link	pending
ex_519396.htm	Edgar Link	pending
ex_519397.htm	Edgar Link	pending
ex_547923.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
opk-20230630.xsd	Edgar Link	pending
opk20230630_10q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
opk-20230630_lab.xml	Edgar Link	unprocessable
opk-20230630_def.xml	Edgar Link	unprocessable
opk-20230630_pre.xml	Edgar Link	unprocessable
opk20230630_10q_htm.xml	Edgar Link	completed
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
x01.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
opk-20230630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OPK
OPKO HEALTH, INC. Stock $opk

2023 Q3 Form 10-Q Financial Statement

#000143774923021962 Filed on August 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPK OPKO HEALTH, INC. Stock $opk

2023 Q3 Form 10-Q Financial Statement

#000143774923021962 Filed on August 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPK
OPKO HEALTH, INC. Stock $opk